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Invasive mycoses have emerged as a major cause of morbidity and mortality. Epidemiological studies have
shown that surgery services have the highest rate of Candida infections in the hospital. In addition to classical
risk factors, heavy Candida colonization, recurrent gastrointestinal perforations, and acute pancreatitis are
frequently associated with invasive candidiasis. Because prompt initiation of antifungal therapy is critical for
cure but difficult to accomplish, prevention of fungal infections may play an important role in this clinical
setting; however, few prophylactic or preemptive studies have been done to date. The choice, route of ad-
ministration, and dose of the antifungal and comparator regimens and the use of clinically relevant and robust
study end points are critical for the trial design. Various criteria have been used to identify patients at risk
of candidiasis: surgical condition, presence of multiple risk factors, colonization indexes, or expected length
of stay in the intensive care unit. Some are not selective enough, and others are time consuming and expensive.
Rigorous selection of high-risk patients is crucial to optimize the risk-benefit ratio of preventive antifungal
strategies. The aim is to maximize chances of reducing morbidity and mortality while minimizing treatment
costs, exposure of low-risk patients to adverse events, and emergence of resistant fungal strains.
Fungi have emerged worldwide as increasingly frequent
causes of nosocomial infections [1–4]. Candida and
Aspergillus are the most common causes of invasive
mycoses. First observed in immunocompromised pa-
tients, primarily in patients with cancer or those un-
dergoing transplantation, opportunistic fungal patho-
gens have now been recognized as a frequent cause of
infections in critically ill and debilitated surgery pa-
tients. In a recent survey conducted by the Fungal In-
fection Network of Switzerland in Swiss tertiary care
hospitals, intensive care units (ICUs) and surgical wards
accounted for about two-thirds of all episodes of can-
didemia [5]. The incidence of candidemia was 5–10
times higher in ICUs than in other wards. In these
clinical settings, Candida is a predominant pathogen,
accounting for 5%–15% of nosocomial infections and
Reprints or correspondence: Dr. Thierry Calandra, Infectious Diseases Service,
Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, CH-
1011, Lausanne, Switzerland (Thierry.Calandra@hospvd.ch).
Clinical Infectious Diseases 2004; 39:S185–92
 2004 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2004/3908S4-0005$15.00
ranking among the 5–10 most frequent bloodstream
pathogens [1].
The most frequent clinical manifestations of invasive
candidiasis in surgery and ICU patients include can-
didemia, intra-abdominal candidiasis, candidal uri-
nary-tract infections, and disseminated candidiasis.
Other manifestations, such as Candida endophthal-
mitis, pulmonary candidiasis, and Candida endocar-
ditis, occur less frequently.
Invasive candidiasis is associated with substantial
morbidity, high crude and attributable mortality (40%–
60% and 30%–40%, respectively), prolonged hospital
stay, and increased health care costs [6–8]. Prompt in-
itiation of antifungal therapy is essential for the control
of infection and a favorable outcome. However, early
diagnosis of invasive candidiasis remains a major chal-
lenge. Conventional microbiological tests, including
blood cultures, lack sensitivity (only 40%–60% among
patients with proven invasive candidiasis). Radiological
manifestations lack specificity, and novel serological
and molecular diagnostic tools still need to be validated
on a large scale. Because invasive candidiasis is a late-
onset and highly lethal nosocomial infection [6, 9, 10],
recent clinical studies have examined the impact of
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Table 1. Sensitivity, specificity, and positive and negative predictive values of
various colonization criteria for prediction of invasive candidiasis in surgery inten-
sive care unit patients.
Criterion Sensitivity Specificity
Positive
predictive
value
Negative
predictive
value
No. of sites colonized by Candida
2 100 22 44 100
3 45 72 50 68
Colonization index 0.5 100 69 66 100
Corrected colonization index 0.4 100 100 100 100
NOTE. Data are %. Adapted from [14].
prophylactic and preemptive treatment strategies. Here, we re-
view the results of clinical studies of antifungal prophylactic
and preemptive therapies in surgery patients at risk of Candida
infections. We also discuss issues related to the design of future
clinical trials in this clinical setting.
RISK FACTORS FOR INVASIVE CANDIDIASIS
In primarily immunocompetent patients, 2 conditions predis-
pose to Candida infection: the colonization of skin and mucous
membranes by Candida and alteration of natural host barriers
(i.e., by wounds, surgery, and insertion of indwelling intravas-
cular and urinary catheters). The gastrointestinal tract and skin
are the most frequent portals for Candida. Risk factors for the
development of fungal infections have been identified [11, 12].
Prolonged treatment with multiple broad-spectrum antibiotics
is known to cause a profound alteration of the endogenous
flora, which promotes the growth of Candida species. Debili-
tating underlying diseases, critically ill status as indicated by a
high APACHE II score, premature birth, acute renal failure and
hemodialysis, intravascular access devices, antacids, total par-
enteral nutrition, and mechanical ventilation have also been
frequently associated with invasive candidiasis [11]. Unfortu-
nately, few of these predisposing factors are sufficiently discri-
minant. Indeed, they also are frequently present in patients in
whom candidiasis will not occur. However, because the onset
of invasive candidiasis is typically preceded by the progressive
accumulation of multiple risk factors over days or weeks, their
recognition may assist clinicians deciding when to implement
preventive measures for a given patient.
Candida colonization was found to play a key role in the
pathogenesis of invasive candidiasis in studies that performed
frequent surveillance cultures at multiple body sites (e.g., or-
opharynx, gastrointestinal tract, urinary tract, respiratory tract,
skin, drains from surgical sites, surgical wounds, and insertion
sites of intravascular access devices) [11, 13–15]. Semiquanti-
tative cultures (i.e., plating of biological specimens by means
of the clock-streak technique and a calibrated loop) are often
used to estimate the degree of colonization, and results are
expressed as light (growth on the first of the 3 inoculation
quadrants), moderate (growth on the first and second of the
3 inoculation quadrants), and heavy growth (growth on all 3
inoculation quadrants) [16]. Pittet et al. [14] have studied the
role of Candida colonization as a predictor of infection in crit-
ically ill surgery patients. Colonization was defined by the pres-
ence of Candida in 3 samples from either the same or dif-
ferent body sites on at least 2 consecutive screening days. Over
a 6-month period, 29 (4.5%) of 650 ICU patients found to be
colonized at multiple body sites were followed prospectively—
18 patients (62%) remained colonized, and 11 (38%) developed
invasive candidiasis. In the group with invasive candidiasis, the
mean APACHE II score at ICU admission was higher (28 
6 vs. 17  4 in colonized controls; P ! .01), the mean duration
of antibiotic therapy and ICU stay were longer (35  14 vs.
16  13 days [P ! .01] and 27.7 vs. 17.5 days [P p .12],
respectively), and the 30-day all-cause mortality was higher
(55% vs. 11%; P p .03). The median duration of Candida
colonization was similar in the 2 groups (29 days [range, 5–
140 days] vs. 25 days [range, 6–70 days]). However, heavy or
increasing quantities of Candida in serial surveillance cultures
occurred in patients with invasive candidiasis more often than
in control patients (91% vs. 44%; P p .02). A colonization
index was calculated by dividing the number of colonized sites
by the number of cultured sites. The mean colonization index
in patients who developed invasive candidiasis was significantly
higher than that in controls (0.70  0.17 vs. 0.47  0.17; P
! .01), yet colonization index values overlap between the 2
groups. A colonization index threshold of 0.5 was reached at
a median of 6 days (range, 2–21 days) before a diagnosis of
invasive candidiasis was made in all patients.
As shown in table 1, the proposed colonization index had a
sensitivity and negative predictive value of 100% to distinguish
patients who will develop invasive candidiasis from those who
are merely colonized. The specificity of the colonization index
was 69%, and the positive predictive value was 66%. Sensitivity,
specificity, positive predictive value, and negative predictive
value all reached 100% when a corrected colonization index
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with a threshold of 0.4 was used. The corrected colonization
index was calculated by multiplying the colonization index by
the ratio of the number of heavily colonized sites (based on
semiquantitative cultures) to the total number of colonized
sites. For example, in a patient in whom 6 sites had been
screened for colonization (e.g., oropharynx, urine, stool, tra-
cheal aspirate, central venous catheter insertion site, and sur-
gical wound) and 4 of them had been found to be colonized
by Candida (e.g., heavily in oropharynx, tracheal aspirate, and
stool and moderately in urine), the colonization index was 0.67
(4 colonized sites/6 cultured sites) and the corrected coloni-
zation index was 0.5 (0.67  3 heavily colonized sites/4 col-
onized sites). Genotyping of Candida strains confirmed that
colonization and fungal invasion are sequential events, because
identical colonizing and invasive Candida genotypes were found
in every patient who later developed invasive candidiasis. If
patients are be colonized concomitantly with pathogenic and
nonpathogenic strains of Candida, then the challenge will be
to distinguish these 2 types of strains. Molecular typing may
help to identify patients who are colonized by invasive versus
noninvasive Candida strains. At present, these sophisticated,
time-consuming, and expensive diagnostic tests remain purely
investigational tools.
Preventive treatment strategies are “double-edged swords”
associated with potential toxicity that promote the emergence
of resistant microorganisms. It is therefore critical to limit their
use to a selected group of patients at high risk of infection.
CANDIDA INFECTIONS AFTER ABDOMINAL
SURGERY
The gastrointestinal tract is a major reservoir of Candida species
and an important portal for intra-abdominal and disseminated
candidiasis. As a commensal of the digestive tract, Candida
may leak into the peritoneal cavity after perforation of a hollow
viscus or surgical section of the intestinal wall. However, under
most circumstances, Candida will be cleared quickly from the
peritoneum. Nevertheless, in some patients, peritoneal seeding
will result in the development of an intra-abdominal Candida
infection, with a risk of dissemination to the bloodstream and
to extra-abdominal tissues and organs [13, 16–21].
In a study of candidemia in nonneutropenic patients, ab-
dominal surgery was found to be a risk factor in one-third of
the patients [22]. However, clinicians have expressed different
views about the clinical significance of Candida isolated from
the peritoneum. Whereas some thought that Candida played a
pathogenic role in patients with intraperitoneal infections and
recommended antifungal therapy [13, 18, 20], others consid-
ered Candida an “innocent bystander” for which no specific
therapy was needed [23, 24]. To help reconcile these apparently
conflicting findings, we prospectively analyzed the clinical
courses of 49 surgery patients with culture of peritoneal fluid
positive for Candida species [16]. The results of this primarily
prospective study are summarized in table 2. Intra-abdominal
candidiasis occurred in 19 cases (39%), whereas Candida was
eliminated spontaneously in 30 patients (61%). Recurrent gas-
trointestinal perforation (47% vs. 10%; P p .005) requiring
multiple surgical interventions and acute pancreatitis (47% vs.
3%; P ! .001) were more frequent in patients with intra-ab-
dominal candidiasis than in patients without it. Furthermore,
the presence of a high initial growth (i.e., moderate or heavy,
as defined above) or an increasing (i.e., from light to moderate
or heavy or from moderate to heavy) amount of Candida in
serial semiquantitative cultures obtained at surgery or from
abdominal drains was found to be an early indicator of infec-
tion. Indeed, positive results of culture for Candida at surgery
(79% vs. 43%; Pp .02), moderate or heavy initial colonization
by Candida (53% vs. 13%; Pp .008), and an increasing quan-
tity of Candida in surveillance cultures (79% vs. 7%; P ! .001)
occurred more frequently in patients who subsequently devel-
oped intra-abdominal candidiasis. Thus, sustained seeding of
the peritoneal cavity with Candida in the context of recurrent
gastrointestinal leakages is a major risk factor for candidiasis
in patients after abdominal surgery. Of note, abdominal can-
didiasis is associated with high mortality rates (27%–77%) [13,
19, 24–26], which strongly argues in favor of antifungal pro-
phylactic or preemptive treatment approaches in such a high-
risk group.
DESIGN OF CLINICAL TRIALS FOR THE
PREVENTION OF INVASIVE CANDIDIASIS IN
SURGERY PATIENTS
Several issues should be considered when designing clinical
trials of antifungal prophylactic and preemptive treatment strat-
egies (figure 1); these are relevant not only for surgery and ICU
patients but also for several other types of patients. These issues
are the identification of a group of high-risk patients who may
benefit from such interventions, the calculation of the sample
size needed to test the study hypothesis, the use of clear-cut
primary and secondary study end points, and the choice of a
control treatment group that respects the principle of equipoise
(i.e., the existence of credible doubt about the relative merits
of the proposed medical interventions). These and several oth-
ers issues have been reviewed recently [27] and here will be
reviewed only in the context of the surgery patient.
Patient selection. Selection of an appropriate patient pop-
ulation to test the study hypothesis is essential. The goal should
be to give prophylaxis or preemptive antifungal therapy to pa-
tients at high risk of candidiasis and to exclude patients who
are unlikely to benefit from therapy but may be unnecessarily
exposed to adverse events, such as drug toxicity and coloni-
zation by resistant Candida strains. Given the excellent efficacy
and safety profiles of azoles, it would be very tempting to use
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Table 2. Clinical characteristics, microbiological data, and outcome for surgery patients with intra-
abdominal candidiasis or with colonization of the peritoneal fluid but no evidence of invasive disease.
Characteristic
Candidiasis
(n p 19)
Candida
colonization
(n p 30) P
Underlying surgical conditions
Gastrointestinal perforation 9 (47) 19 (63) NS
Recurrent gastrointestinal perforation 9 (47) 3 (10) .005
Acute pancreatitis 9 (47) 1 (3) !.001
Other abdominal conditions 2 (11) 10 (33) .09
Emergency surgery 15 (79) 26 (87) NS
Microbiological dataa
Candida growth in peritoneal fluid
At surgery 15 (79) 13 (43) .02
From drains 4 (21) 17 (57) .02
Light vs. moderate or heavy growth on first culture 9 (47) vs. 10 (53) 26 (87) vs. 4 (13) .008
Increasing in subsequent cultures 15 (79) 2 (7) !.001
Outcome
Failure of surgical drainage without antifungal treatment 16 (84) 0 !.001
Candida peritonitis 11 (58) NA
Intra-abdominal Candida abscess 5 (26) NA
Success with reintervention and antifungal therapy 9 (47) NA
Mortality
Overall 12 (63) 3 (10) !.001
Death due to infection 8 (42) 1 (3) .001
Death due to fungal infection 7 (37) NA
NOTE. Data are no. of patients (%). NA, not applicable; NS, not significant. Adapted from [16].
a Based on semiquantitative cultures, as described in the text.
them as prophylactic agents on a large scale. However, any
abuse of these agents could lead to the emergence of dose-
dependent susceptible (Candida glabrata) or resistant (Candida
krusei) species, which would result in a decreased efficacy of
this remarkable class of antifungal agents. This phenomenon
has been reported in neutropenic patients with cancer who
received fluconazole prophylaxis and has been associated with
an increased mortality [28, 29]. Other authors have made sim-
ilar observations in general hospital wards and ICUs [30, 31].
In contrast, in the 10-year survey conducted by the Fungal
Infection Network of Switzerland [5], Candida albicans has
remained the predominant species (65%–70% of all blood-
stream isolates), and the proportions of C. glabrata and C.
krusei infections remained stable (15% and 2%, respectively),
despite a significant increase in fluconazole consumption. Al-
though the impact of azole consumption on recent changes in
the epidemiology of Candida infections remains debatable [32],
caution about any indiscriminate use of these agents is war-
ranted. Selection of high-risk patients will also reduce trial ex-
penses and future treatment costs, which in today’s economic
environment are nontrivial issues for study sponsors and part-
ners of the public and private sectors of the health care system.
Few studies have examined the impact of antifungal pro-
phylaxis or preemptive therapy in surgery, trauma, or ICU
patients. As reviewed recently [27], several of these studies were
underpowered to demonstrate an impact of antifungal pro-
phylaxis, if it existed. Savino et al. [33] compared oral clotri-
mazole, ketoconazole, and nystatin with placebo for patients
expected to stay for 48 h in a surgical ICU. Candidiasis oc-
curred in only 2% of placebo recipients, and no benefit of
prophylaxis was demonstrated. Slotman and Burchard [34]
compared ketoconazole prophylaxis with placebo in 57 surgical
ICU patients who were selected on the basis of the presence
of 3 risk factors at baseline. Candida colonization occurred
in 8 (30%) of 27 ketoconazole-treated patients and in 18 (60%)
of 30 controls (Pp .03). Invasive Candida infections developed
in 5 (17%) of 30 placebo patients but in none of the patients
treated with ketoconazole (Pp .05). These results suggest that
6 patients should be treated with ketoconazole to prevent one
episode of invasive candidiasis. Of note, in that study, the fre-
quency of invasive candidiasis in the placebo group (17%) was
also 8 times higher than that observed in the study by Savino
et al. [33], suggesting that the presence of multiple risk factors
may help to predict a higher incidence of invasive candidiasis.
However, this requires a laborious and continuous screening
of numerous parameters. More recently, Pelz et al. [35] ran-
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Figure 1. Issues to be considered in the design of clinical trials of antifungal prophylactic and preemptive treatment strategies. ICU, intensive care
unit.
domized 260 surgery patients, expected to stay in the ICU for
13 days, to receive oral fluconazole prophylaxis (800 mg first
dose, followed by 400 mg/day) or placebo. In the intention-
to-treat analysis, 11 fungal infections (9%) occurred in the
fluconazole group versus 20 (16%) in the placebo group (P !
.05). The number of patients who needed treatment to prevent
one episode of Candida infection was 15. Mortality was similar
in the 2 treatment groups.
Following up on our previous observation that at least one-
third of patients with recurrent gastrointestinal perforation de-
velop Candida peritonitis, we performed a randomized, double-
blind, placebo-controlled study among high-risk surgery
patients with recurrent gastrointestinal perforations or anas-
tomotic leakages (table 3) [36]. Patients were selected on the
basis of a simple and broadly applicable criterion, namely, a
clinically suspected or surgically confirmed recurrent gastro-
intestinal perforation or anastomotic suture leakage. Patients
received either fluconazole (400 mg/day iv, np 23) or placebo
(np 20). Patients’ characteristics—including classical risk fac-
tors for Candida infections, number of previous surgical in-
terventions, APACHE II score, and growth of Candida in the
intra-abdominal fluid—and the number of reinterventions dur-
ing the study were similar in the 2 groups. At study entry, 60%
of the patients were not colonized with Candida and thus may
have benefited from a true antifungal prophylaxis. In the other
patients (40%), treatment was probably more preemptive than
truly prophylactic, because they were already colonized with
Candida at enrollment. However, experts’ opinions diverge
about definitions of prophylaxis and preemptive therapies.
Among patients who were not colonized at study entry, Candida
was isolated from surveillance cultures during prophylaxis from
62% of the placebo group and 15% of the fluconazole group
(Pp .04). Intra-abdominal candidiasis developed in 1 flucon-
azole-treated patient (4%) and in 7 placebo-treated patients
(35%; P p .02). No death attributed to candidiasis occurred
in the fluconazole group, but 4 patients (20%) died from intra-
abdominal candidiasis in the placebo group (P p .04). The
reduction of the incidence of candidiasis with fluconazole was
substantial (8-fold), and the number of patients who needed
to be treated to prevent one episode of intra-abdominal can-
didiasis was only 3. Data on the reduction of mortality should
be interpreted with great caution because of the small numbers
of patients enrolled and the impact of possible confounding
variables on a patient’s outcome. Overall, this study indicates
that it is possible to identify, by means of straightforward clin-
ical criteria, a subgroup of post–abdominal surgery patients at
high risk of Candida infections who would benefit from an-
tifungal preventive therapies.
Alternatively, patients could be selected for a preventive in-
tervention when they become heavily colonized with Candida
in surveillance cultures. In our initial study, 19 (39%) of 49
patients with Candida isolated from postsurgical surveillance
cultures of the peritoneal fluid developed intra-abdominal can-
didiasis [16]. Both the presence of colonization at baseline and
the persistence or emergence of colonization in follow-up cul-
tures have been found to be associated with subsequent invasive
candidiasis. These results suggested that specimens obtained at
surgery and thereafter may help to predict who will or will not
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Table 3. Summary of the results of a clinical trial comparing fluconazole with
placebo for prophylaxis of invasive candidiasis in surgery patients with recurrent
gastrointestinal perforation or anastomotic leak.
Factor
Fluconazole,
400 mg daily iv
(n p 23)
Placebo
(n p 20) P
Clinical characteristics
No. of surgical interventions at
study entry, median (range) 2 (1–7) 2 (2–4) NS
APACHE II score at baseline, median (range) 13 (4–24) 13 (6–24) NS
Reintervention during study 8 (35) 7 (35) NS
Microbiological data
Candida in peritoneal fluid
At study entry 10 (43) 7 (35) NS
During study 7 (30) 14 (70) .01
Persistence 5/10 (50) 6/7 (86) NS
Emergence 2/13 (15) 8/13 (62) .04
End points
Intra-abdominal candidiasis 1 (4) 7 (35) .02
Candida only 1 (4) 1 (5) NS
Candida and bacteria 0 6 (30) .04
Candidiasis secondary to peritonitis 0 2 (10) NS
Overall mortality 7 (30) 10 (50) NS
Death due to intra-abdominal candidiasis 0 4 (20) .04
NOTE. If not indicated otherwise, data are no. (%) or no./total (%). NS, not significant. Adapted
from [36].
develop invasive candidiasis. Pittet et al. [14] also performed
routine surveillance cultures among 650 surgical ICU patients
and found that 4.5% were heavily colonized with Candida. The
incidence of invasive candidiasis in colonized patients was very
high (11 [38%] of 29 patients). Moreover, the authors found
a correlation between 2 colonization indexes and the occurrence
of invasive candidiasis. The incidence of invasive candidiasis in
these 2 studies (39% and 38%) was 20–40 times higher than
that of a general ICU population (1%–2%). If a 2% incidence
in the surgical ICU population (n p 650) studied by Pittet et
al. [14] is assumed, 13 invasive candidiasis episodes would have
been anticipated during the period of observation, and 11 ep-
isodes of candidiasis occurred among 29 heavily colonized pa-
tients (38%). The extrapolated sensitivity, specificity, and pos-
itive and negative predictive values of colonization for
prediction of invasive candidiasis would be 85%, 97%, 38%,
and 100%, respectively. Therefore, this colonization index was
associated with high sensitivity, specificity, and negative pre-
dictive value (consistent with the well-known observation that
colonization precedes infection), but a low positive predictive
value. One limitation of the colonization index is that it is fairly
labor-intensive and expensive when used on a large scale. A
summary of the pros and cons of the screening methods most
frequently used to identify surgery patients at risk of invasive
candidiasis is shown in table 4.
End points, sample size, and choice of antifungal agents.
Development of invasive candidiasis should be the primary end
point of any prophylactic or preemptive antifungal therapy trial.
For example, intra-abdominal candidiasis would be a relevant
end point in post–abdominal surgery patients, whereas can-
didemia would be preferred as an end point in a more het-
erogeneous group of ICU patients. Several secondary end points
might be considered, including the emergence or the persistence
of Candida colonization, appearance of resistant Candida
strains, time to development of Candida infection, use of em-
pirical antifungal therapy, adverse events, morbidity, mortality,
and length of ICU and hospital stay. To facilitate comparisons
of outcome among studies, investigators should, whenever pos-
sible, use either consensus or widely accepted definitions of
invasive candidiasis. The diagnostic criteria for opportunistic
invasive fungal infections in immunocompromised hosts pub-
lished by the European Organization for Research on Treatment
of Cancer Invasive Fungal Infection Group and the Mycoses
Study Group of the National Institute of Allergy and Infectious
Diseases [37] are an example of such definitions that have
contributed to major progress in clinical research of invasive
mycoses in patients with cancer or hematologic malignancies.
As in any other clinical investigations, the sample size should
be calculated on the basis of the anticipated incidence of the
primary study end point in the control population. The number
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Table 4. Comparison of different screening methods for the identification of surgery patients at risk of invasive candidiasis.
Factor
Screening method
Anticipated duration
of ICU stay
Presence of
multiple risk factors
Specific
surgical conditions Candida colonization
Basis for selection of patients Clinical evaluation at ICU
admission
Medical history and clinical,
laboratory, and radiological
findings
Surgical evaluation Routine surveillance
cultures
No. of parameters required for evaluation 1 110 1 1
Practical feasibility Straightforward, but difficult
to predict
Need for continuous
follow-up
Straightforward Time-consuming and
expensive
Expected incidence of invasive candidiasis ∼2%–15% ∼10%–20% ∼30%–40% ∼30%–40%
No. needed to treat to prevent one episode
of invasive Candida infection
15–50 5–10 2–5 2–5
NOTE. ICU, intensive care unit. Derived from [14, 33–36].
needed to treat to prevent one episode of primary and sec-
ondary end points could be calculated on the basis of the ex-
pected reduction of the rate of invasive candidiasis within the
experimental treatment arm. Examples of number needed to
treat derived from previous clinical trials are shown in table 4.
The choice of the antifungal agent, route of administration
(intravenous vs. oral), and dosage should be based on epide-
miological, microbiological, pharmacological (i.e., pharmaco-
kinetics, pharmacodynamics, bioavailability), preclinical, and
clinical data. Systemic and tissue concentrations of antifungal
agents should be high enough to prevent bloodstream and tissue
invasion. Nonabsorbable oral antifungal agents, such as the
polyenes (amphotericin B or nystatin), act topically in the gas-
trointestinal tract. These agents have had a limited impact in
reducing the incidence of invasive candidiasis in neutropenic
and nonneutropenic (i.e., surgery and ICU) patients [27, 33,
38, 39]. Antifungal agents for whom both an intravenous and
an oral formulation are available are the most attractive for
prevention of Candida infections in surgery patients, because
they allow a change from iv to oral therapy as soon as gastro-
intestinal motility and function are restored. Among the ex-
isting drugs, fluconazole fulfills all of these prerequisites and,
on the basis of the available data, would be the drug of first
choice. Inconsistent oral bioavailability would be a limitation
for the use of other azoles (such as itraconazole and posacon-
azole) in the postsurgical patient. Moreover, the administration
of azoles might be problematic in centers with a high incidence
of fluconazole-resistant Candida species and the possibility of
cross resistance. Caspofungin, an echinocandin, has been shown
to be efficacious for the treatment of invasive candidiasis due
to azole-susceptible and azole-resistant Candida species. This
class of antifungal agents might also be considered for pro-
phylaxis but can be given intravenously only. Treatment cost
is another factor to be taken into account in the design of
prophylactic trials. Finally, given that azole prophylaxis has been
shown in several studies to reduce the incidence of fungal in-
fections, it may become difficult to justify the use of placebo
as control therapy in certain populations of surgery and ICU
patients at high risk.
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